The European Society for Medical Oncology (ESMO) Congress 2025 was grandly held in Berlin, marking another wave of scientific innovation across the field of oncology.In hematology, several exciting advances drew attention—from uncovering the mechanisms of CAR-T resistance and exploring dual-target immunotherapies, to studies on precision treatment discontinuation in multiple myeloma and single-cell immune atlas mapping that deepens our understanding of hematologic malignancies. Together, these studies highlight continuous innovation in medical science and bring new hope for improving diagnosis and treatment in hematologic diseases.To further focus on major breakthroughs in hematology and foster academic exchange, Oncology Frontier – Hematology News invited Dr. Sicong Zhang, from Professor Huilai Zhang’s research group at Tianjin Medical University Cancer Institute and Hospital, to discuss the innovation and clinical significance of a new study presented at ESMO 2025, as well as to share his insights into future trends in the field.

In hematology, this year’s highlights encompassed several cutting-edge research directions—from unraveling the mechanisms of CAR-T resistance and exploring dual-target immunotherapies that may enhance precision and efficacy, to studies on treatment-free remission in multiple myeloma, and the creation of single-cell immune atlases offering novel insights into hematologic disease mechanisms. These achievements collectively reflect the continued progress and innovation in biomedical science and bring new hope for patients with hematologic malignancies.